 Revolution Medicines NASDAQ: RVMD shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of 6.08 year-over-year and sales 12.66 million up from 12.51 million year-over-year. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. 